These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37816862)

  • 1. Sodium-glucose co-transporter 2 inhibitor add-on therapy for metformin delays diabetic retinopathy progression in diabetes patients: a population-based cohort study.
    Li JX; Hung YT; Bair H; Hsu SB; Hsu CY; Lin CJ
    Sci Rep; 2023 Oct; 13(1):17049. PubMed ID: 37816862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
    Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
    Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Diabetic Retinopathy in Patients With Type 2 Diabetes After SGLT-2 Inhibitors: A Nationwide Population Cohort Study.
    Huang ST; Bair PJ; Chang SS; Kao YN; Chen SN; Wang IK; Chiu CW; Chang CT; Shih YH; Li CY; Yu TM
    Clin Pharmacol Ther; 2024 Jan; 115(1):95-103. PubMed ID: 37804230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world risk of lower-limb amputation associated with sodium-glucose cotransporter 2 inhibitors versus metformin: A propensity score-matched model analysis in Japan.
    Mizutani G; Horii T; Oikawa Y; Atsuda K; Shimada A
    J Diabetes Investig; 2022 Dec; 13(12):2000-2009. PubMed ID: 36124433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
    Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sodium-glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis.
    Fakhrolmobasheri M; Abhari AP; Manshaee B; Heidarpour M; Shafie D; Mohammadbeigi E; Mozafari AM; Mazaheri-Tehrani S
    Acta Diabetol; 2023 Feb; 60(2):191-202. PubMed ID: 36264350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials.
    Qian BB; Chen Q; Li L; Yan CF
    Osteoporos Int; 2020 Dec; 31(12):2313-2320. PubMed ID: 32780153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin Treatment Is Associated with a Decreased Risk of Nonproliferative Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
    Fan YP; Wu CT; Lin JL; Hsiung CA; Liu HY; Lai JN; Yang CC
    J Diabetes Res; 2020; 2020():9161039. PubMed ID: 32377525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials.
    Scheen AJ
    Diabetes Metab; 2020 Jun; 46(3):186-196. PubMed ID: 32007623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: A Descriptive Analysis in the UK CPRD.
    Farmer RE; Beard I; Raza SI; Gollop ND; Patel N; Tebboth A; McGovern AP; Kanumilli N; Ternouth A
    Clin Ther; 2021 Feb; 43(2):320-335. PubMed ID: 33581878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
    Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
    JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country.
    Zaghloul N; Awaisu A; Mahfouz A; Alyafei S; Elewa H
    Int J Clin Pharm; 2022 Dec; 44(6):1342-1350. PubMed ID: 36169802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of sodium-glucose co-transporter-2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes.
    Park S; Jeong HE; Bea S; Yu OHY; Cho YM; You SC; Man KKC; Shin JY
    Diabetes Obes Metab; 2023 Nov; 25(11):3248-3258. PubMed ID: 37503763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands.
    van Schoonhoven AV; Schöttler MH; Serné EH; Schrömbges PPG; Postma MJ; Boersma C
    J Med Econ; 2023; 26(1):547-553. PubMed ID: 36987694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent Oral Hypoglycemic Agents for Microvascular Complication: Sodium-Glucose Cotransporter 2 Inhibitors for Diabetic Retinopathy.
    Cho EH; Park SJ; Han S; Song JH; Lee K; Chung YR
    J Diabetes Res; 2018; 2018():6807219. PubMed ID: 30622970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.
    Perais J; Agarwal R; Evans JR; Loveman E; Colquitt JL; Owens D; Hogg RE; Lawrenson JG; Takwoingi Y; Lois N
    Cochrane Database Syst Rev; 2023 Feb; 2(2):CD013775. PubMed ID: 36815723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis.
    Wang C; Zhou Y; Kong Z; Wang X; Lv W; Geng Z; Wang Y
    Diabetes Obes Metab; 2019 Apr; 21(4):1018-1026. PubMed ID: 30565382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium Glucose Transporter-2 Inhibitors (SGLT2Is)-TLRs Axis Modulates Diabetes.
    Niknejad A; Hosseini Y; Shamsnia HS; Kashani AS; Rostamian F; Momtaz S; Abdolghaffari AH
    Cell Biochem Biophys; 2023 Dec; 81(4):599-613. PubMed ID: 37658280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
    De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
    Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.